1. Scrip
  2. >>ESG

AstraZeneca Looks To Take Sector Lead In Reducing Greenhouse Gas Emissions

 
• By Joseph Haas

Via a partnership with Vanguard Renewables, AstraZeneca is converting its US locations to renewable natural gas, part of a goal to achieve net zero for carbon emissions by 2045.

Green energy
AstraZeneca intends to reduce greenhouse gas usage by 2030 • Source: Shutterstock

AstraZeneca PLC is trying to take a leadership role within the biopharmaceutical sector on the issue of reducing greenhouse gas emissions, with a new initiative to convert all of its US facilities to renewable natural gas, i.e., biogas, by 2026, with greater carbon-reduction goals set for 2030 and 2045. The large pharma is partnering with Vanguard Renewables on the effort and said its suppliers and contractors will need to play a role in achieving the longer-term goals.

As part of its Ambition Zero Carbon initiative, AstraZeneca is converting its manufacturing sites, R&D facilities and office buildings in the US from natural gas to renewable natural gas (RNG) – derived from waste from farms as well as food and beverage factories – with Vanguard using a process AstraZeneca executive Pam Cheng likens to fermentation to produce the RNG

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 
• By Anju Ghangurde

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Podcast: Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual

 
• By Vibha Ravi

In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’